F-18 Flornaptitril (F-18 FNT)
Detection of tau and amyloid pathology for predicting progression in Mild Cognitive Impairment due to Alzheimer's Disease or Chronic Traumatic Encephalopathy
Pre-clinical / IND-enablingActive
Key Facts
Indication
Detection of tau and amyloid pathology for predicting progression in Mild Cognitive Impairment due to Alzheimer's Disease or Chronic Traumatic Encephalopathy
Phase
Pre-clinical / IND-enabling
Status
Active
Company
About CereMark Pharma
CereMark Pharma is a private, pre-revenue biotech developing precision PET imaging diagnostics for neurodegenerative diseases. Its core asset is F-18 Flornaptitril, a dual tau/amyloid biomarker intended to predict disease progression in patients with Mild Cognitive Impairment, particularly for Alzheimer's and CTE. The company is led by founders with deep expertise in radiopharmaceuticals and brain injury law, and is preparing to initiate clinical trials to advance its drug candidate toward FDA approval.
View full company profile